Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)

<!–

–>

<!–

• Page Last Updated: 05/06/2013

–>
Page Last Updated: 05/06/2013
<!–

–>

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.